[ET Net News Agency, 22 October 2025]  CSPC PHARMA (01093) fell 4.9% to HK$8.48.
  It hits an intra-day low of HK$8.47, hitting an 1-month low, and an intra-day high of 
HK$9. The total shares traded was 96.96 million, with a value of HK$837.38m. The active 
buy/sell ratio is 47:53, with net selling turnover of HK$56.35m. CLSA LTD accounts for  
greatest net responsive buying turnover of HK$43.65m, with volume weighted average price  
of HK$8.641. JEFFERIES HK accounts for greatest net responsive selling turnover of  
HK$23.74m, with volume weighted average price of HK$8.59. The stock has fallen a combined 
6% over the past 2 consecutive trading days.
  The Hang Seng Index now fell 341 points, or 1.3% to 25,686; the Hang Seng China 
Enterprises Index now fell 131 points, or 1.4% to 9,171.
  
          Basic Information 
          ================= 
  
  ----------------------------------
  Nominal    8.480 % Chg     -4.93% 
  High       9.000 Low        8.470 
  Shares Tr 96.96m Turnover 837.38m 
  10-D SMA   8.988 %H.V      46.450 
  20-D SMA   9.168 VWAP       8.636 
  50-D SMA   9.891 RSI14     37.259 
  ----------------------------------
Status: Hitting an 1-month low, active buy/sell ratio is 47:53, with net selling turnover 
of HK$56.35m, falling a combined 6% over the past 2 consecutive trading days
  
Performance of stocks in the same sector or of relevance
========================================================
  
  Stock (Code)            Price (HK$) Change (%)
  ----------------------------------------------- 
  CSPC PHARMA (01093)            8.48      -4.93
  SINO BIOPHARM (01177)          7.15      -3.38
  HENGRUI PHARMA (01276)        76.05      -2.62
  3SBIO (01530)                 27.76      -2.53
  INNOVENT BIO (01801)          83.95      -3.39
  WUXI BIO (02269)              35.62      -1.11
  WUXI APPTEC (02359)          104.30      -1.23
  HANSOH PHARMA (03692)         34.76      -3.18
  BEONE MEDICINES (06160)      182.90      -3.74
  AKESO (09926)                115.70      -3.18
  ----------------------------------------------- 
  (ed)



 
 